MAPT and Alzheimer disease: Unfortunately, there are few clinical studies on the effects of rhEPO administration in patients with AD, which have focused on the treatment of dementia symptoms and scarcely diminish the presence of characteristic hallmarks (Aβ and tau-p aggregation) of this pathology [172,173,174,175].